Study design
obesity, overweight
OBESITY
This randomised, double-blind, placebo-controlled phase 2 study was designed to evaluate the efficacy and safety of mazdutide in Chinese overweight adults or adults with obesity. The study included a 3-week screening period, a 2-week lead-in period, a 24-week treatment period and a 12-week off-treatment follow-up period (Fig. 